Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Radiation therapy uses high-energy x-rays to kill tumor cells. Irinotecan may make tumor
cells more sensitive to radiation therapy. Giving irinotecan together with whole-brain
radiation therapy may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of irinotecan when
given together with whole-brain radiation therapy and to see how well they work in treating
patients with brain metastases from solid tumors. (The study of side effects and best dose
has ended as of 4/15/05)